Kazia Therapeutics Limited American Depositary Shares
KZIAStock
$13.12+24.44%52W
Market Cap$106.64M
P/E—
Div yield—
Beta2.15
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)91.74%
Price vs S&P 500 (4W)-2.99%
VGM Score49.50
Market Capitalization$106.64M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.11
4.11
4.10
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
KZIAKazia Therapeutics Limited American Depositary Shares | F | C | A | $13.12 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Kazia Therapeutics is an oncology-focused biotechnology company developing targeted cancer therapies. Its lead program, Paxalisib, is an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway designed to treat brain cancers. The company maintains operations in Australia and the United States and has a portfolio of additional development candidates across various cancer indications.